Skip to main navigation Skip to search Skip to main content

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia

  • F. J. Giles*
  • , R. T. Swords
  • , A. Nagler
  • , A. Hochhaus
  • , O. G. Ottmann
  • , D. A. Rizzieri
  • , M. Talpaz
  • , J. Clark
  • , P. Watson
  • , A. Xiao
  • , B. Zhao
  • , D. Bergstrom
  • , P. D. Le Coutre
  • , S. J. Freedman
  • , J. E. Cortes
    • *Corresponding author for this work
  • Trinity College Dublin
  • University of Miami
  • Sheba Medical Center at Tel Hashomer
  • Friedrich Schiller University Jena
  • Goethe University Frankfurt
  • Duke University
  • University of Michigan, Ann Arbor
  • Merck
  • Charité – Universitätsmedizin Berlin
  • University of Texas MD Anderson Cancer Center

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Fingerprint

Dive into the research topics of 'MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology